Home/ Stocks/ FHTX

Foghorn Therapeutics Inc. Common Stock

FHTX XNAS

$6.07 +0.41 (+7.36%) ▲ 15-min delayed

Open

$5.64

High

$6.17

Low

$5.51

Volume

280.9K

Market Cap

$330.78M

About Foghorn Therapeutics Inc. Common Stock

Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 106 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$3.27M	$-19,875,000	$-0.29
FY 2025	$30.91M	$-74,283,000	$-1.18
Q3 2025	$8.15M	$-15,849,000	$-0.25
Q2 2025	$7.56M	$-17,936,000	$-0.28

Earnings & Analyst Ratings

Next Earnings: Tue, Nov 3, 2026

Calendar →

Related Market News

No specific coverage for FHTX yet. Check out our latest market news or earnings calendar.

Get FHTX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Foghorn Therapeutics Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.